Thu, Oct 23, 2014, 5:47 AM EDT - U.S. Markets open in 3 hrs 43 mins

Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics Inc. Message Board

  • chumpsrus2000 chumpsrus2000 Jun 4, 2012 10:00 AM Flag

    Awfully quit here...

    Co's indicated that they will release a PR after the data presentation today. The presentation will go from 11:15 - 12:15 EST. You would think that they would release the PR either before or after the market closes but I guess we shall see

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
      Date/Time: Monday, June 4, 2012; 10:30 AM — 10:45 AM (CT)
      Location: E354a
      Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. Dr. Samantha Mary Jaglowski et al. The Ohio State University, Columbus, Ohio.
      Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)
      Date/Time: Friday, June 1, 2012; 4:30 PM — 5:30 PM (CT)
      Location: S405
      Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study. Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas....Patience Is A Virtue..We will know soon enough..

      • 2 Replies to jgmtruth
      • Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
        Date/Time: Monday, June 4, 2012; 10:15 AM — 10:30 AM (CT)
        Location: E354a
        Abstract # 6507: The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naive chronic lymphocytic leukemia patients: Interim results of a phase Ib/II study. Dr. John C. Byrd et al., The Ohio State University, Columbus, Ohio.
        This Abstract was selected to be presented at the "Best of ASCO Meetings."

        Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
        Date/Time: Monday, June 4, 2012; 10:30 AM — 10:45 AM (CT)
        Location: E354a
        Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. Dr. Samantha Mary Jaglowski et al. The Ohio State University, Columbus, Ohio.

        Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)
        Date/Time: Friday, June 1, 2012; 4:30 PM — 5:30 PM (CT)
        Location: S405
        Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study. Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.

      • Oops ..Most important.Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
        Date/Time: Monday, June 4, 2012; 10:15 AM — 10:30 AM (CT)
        Location: E354a
        Abstract # 6507: The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naive chronic lymphocytic leukemia patients: Interim results of a phase Ib/II study. Dr. John C. Byrd et al., The Ohio State University, Columbus, Ohio.
        This Abstract was selected to be presented at the "Best of ASCO Meetings."

 
PCYC
115.13-1.43(-1.23%)Oct 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.